Thomas M Stepien Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 2 months, 1 week ago
Thomas M Stepien has an estimated net worth of at least $10.2 million*, as of July 1, 2026. They own 589,096 shares of AMPX stock. They have sold 98,606 shares of AMPX stock since 2021, for an estimated $1.0 million.
Thomas M Stepien $AMPX SEC Form 4 Insider Trading
Thomas M Stepien has filed a total of 5 insider trades in $AMPX since 2021. Their most recent trade was a sale of 23,529 shares, made on Aug 21, 2026. Their largest trade was a sale of 60,702 shares, made on May 21, 2026. We estimate that they now own 589,096 shares of $AMPX, worth an estimated $9.2 million.
Insider Trading at $AMPX
There have been a total of 122 insider trades reported at $AMPX since 2021, with 0 shares purchased and 10.9 million shares sold. The most active insider traders in $AMPX stock have been Jonathan Bornstein, Constantin Ionel Stefan, and Kang Sun. The most recent trade was a sale of 29,681 shares reported by Constantin Ionel Stefan (Chief Technology Officer), made on Aug 21, 2026.
History of Insider Stock Trades by Thomas M Stepien
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
AMPX
|
Sale | 23,529 | Aug 21, 2026 | Aug. 25, 2026, 6:01 p.m. |
|
AMPX
|
Sale | 8,000 | Aug 24, 2026 | Aug. 25, 2026, 6:01 p.m. |
|
AMPX
|
Sale | 2,000 | Jun 04, 2026 | June 5, 2026, 4:57 p.m. |
|
AMPX
|
Sale | 4,375 | May 27, 2026 | May 28, 2026, 6:22 p.m. |
|
AMPX
|
Sale | 60,702 | May 21, 2026 | May 26, 2026, 7:03 p.m. |
$AMPX Executives and Stock Owners with Insider Trades
-
Jonathan Bornstein, President of Amprius Lab
-
Constantin Ionel Stefan, Chief Technology Officer
-
Kang Sun, Chief Executive Officer
-
Sandra Wallach, Chief Financial Officer
-
Thomas M Stepien, Chief Executive Officer
-
Kang Sun, See Remarks
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.